Advertisement
UK markets open in 1 hour 3 minutes

  • NIKKEI 225

    37,968.49
    +340.01 (+0.90%)
     

  • HANG SENG

    17,660.76
    +376.22 (+2.18%)
     

  • CRUDE OIL

    84.00
    +0.43 (+0.51%)
     

  • GOLD FUTURES

    2,347.70
    +5.20 (+0.22%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • Bitcoin GBP

    51,580.14
    +210.51 (+0.41%)
     

  • CMC Crypto 200

    1,388.97
    +6.40 (+0.46%)
     

  • NASDAQ Composite

    15,611.76
    -100.99 (-0.64%)
     

  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

AstraZeneca bets on gene editing for broad range of new drugs

Reuters - UK Focus

LONDON, Jan 29 (Reuters) - AstraZeneca (NYSE: AZN - news) said on Thursday it had struck four research collaborations in the hot area of genome editing as it bets on a new technology to deliver better and more precise drugs for a range of diseases.

The academic and commercial tie-ups will allow AstraZeneca to use so-called CRISPR technology across its entire drug discovery platform in areas such as oncology, cardiovascular, respiratory and immune system medicine. (Reporting by Ben Hirschler; Editing by David Holmes)